News 2024-03-02
Porton Pharma Solutions Joined the SBTi to Drive Climate Action
Porton Pharma Solutions Ltd. is thrilled to announce its commitment to climate action by joining the Science Based Targets initiative (SBTi). By aligning our emissions reduction targets with the Paris Agreement goals on limiting global warming to 1.5°C, we aim to contribute towards creating a sustainable and low-carbon future.
By joining the SBTi, Porton commits to setting ambitious, science-based greenhouse gas (GHG) emissions reduction near term targets in line with the goals outlined in the Paris Agreement. These targets will be developed using the most up-to-date climate science available and will ensure that our emissions trajectory is consistent with the global effort to limit temperature rise below dangerous levels.
"We are excited to join the SBTi and commit to science-based targets, which remarks another milestone in Porton’s actions to mitigate climate change, " said Oliver Ju, Chairman of Porton. "By doing so, we are taking concrete actions to address climate change and contribute to the global collective effort. In 2023, we established a task force to comprehensively advance and implement our initiatives concerning climate change. We believe that businesses have a crucial role in leading the transition to a sustainable future, and we are committed to doing our part."
As part of our commitment to the SBTi, Porton will regularly measure and report our progress towards our targets, providing transparency and accountability to our stakeholders. Through this process, we will identify opportunities for innovation and efficiency, promoting sustainable practices throughout our operations and supply chain.
About SBTi
The Science Based Targets initiative (SBTi) is a partnership between CDP, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF), aiming to drive ambitious climate action in the private sector by enabling organizations to set science-based emissions reduction targets.
Others
More
News 2026-10-24
Porton Shared Complex Bioconjugate Development Strategies at the 17th World ADC San Diego
As a conference partner, Porton contributed a scientific presentation and poster addressing the technical challenges of developing ADCs and emerging bioconjugates.

News 2026-10-22
Simplifying Synthesis with Radical Cross-Coupling: Prof. Phil S. Baran of Scripps Research Lectures at Porton
The event was hosted by Dr. Yongli Zhong, CSO, and attended by Mr. Oliver Ju, Chairman and CEO; Mr. Yunxing Yin, VP and Head of the Small Molecule Platform, and more than 200 R&D and technical staff.